Protagonist Therapeutics, Inc. - Common Stock (PTGX)
51.06
+0.91 (1.81%)
NASDAQ · Last Trade: Jun 3rd, 6:15 PM EDT
Detailed Quote
Previous Close
50.15
Open
49.91
Bid
51.05
Ask
51.08
Day's Range
49.65 - 52.08
52 Week Range
27.00 - 60.60
Volume
1,467,630
Market Cap
3.16B
PE Ratio (TTM)
65.46
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
811,970
Chart
About Protagonist Therapeutics, Inc. - Common Stock (PTGX)
Protagonist Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapeutic solutions for patients suffering from a range of serious diseases. The company employs a unique approach that combines peptide-based drug discovery with advanced technologies to create targeted therapies, aiming to address unmet medical needs in areas such as gastrointestinal conditions, inflammatory diseases, and oncology. With a commitment to scientific rigor and collaboration, Protagonist is advancing its pipeline of drug candidates through clinical trials, striving to bring new treatments to market that can significantly improve patient outcomes. Read More
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session (LBA3) at 2:09 pm CDT today.
NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference taking place June 3-5, 2025, in New York, NY. The Company will also participate in one-on-one meetings.
Interesting Technical Analysis finding for PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX): Indications Suggest NASDAQ:PTGX Could Be on the Verge of a Breakout.
Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st
NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2025.
NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that on April 15, 2025 (the "Grant Date"), it issued an equity inducement award to a new employee upon his commencement of employment with the Company in accordance with the terms of his employment offer letter. The award was granted under the Company's Amended and Restated 2018 Inducement Plan, which was adopted on May 29, 2018, and amended on February 18, 2020 and February 15, 2022.
Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.
84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Clinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28
Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study
